Sign in
CompletedNo phase

Sleep Efficacy Randomized Evaluation of a Novel Digital Therapeutic for Insomnia

Key facts

Who runs it
BELL Therapeutics Inc.
Where
South Korea6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
116 people enrolled
Started
4 Mar 2026
Ended
24 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • BELL-001 Digital Therapeutic
  • Sham Digital Therapeutic
Record updated
27 August 2026

Who can take part

Age
19 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 19 to 75 years
  • Clinical diagnosis of insomnia disorder according to ICD-10 criteria (non-organic insomnia or sleep initiation/maintenance disorder)
  • Insomnia Severity Index (ISI) score ≥ 15 at screening
  • Reports difficulty initiating or maintaining sleep at least 3 nights per week for ≥ 3 months
  • Willing and able to use a smartphone-based digital therapeutic during the pre-sleep period for 4 weeks
  • Able to provide informed consent and comply with study procedures

Who cannot take part

  • Use of sleep-inducing medications or CNS-active drugs that cannot be stabilized or discontinued per protocol
  • Other primary sleep disorders (e.g., obstructive sleep apnea, restless legs syndrome, narcolepsy, circadian rhythm sleep-wake disorders)
  • Major psychiatric disorders that may interfere with study assessment (e.g., psychotic disorders, bipolar disorder, severe major depressive episode)
  • Substance use disorder, including alcohol or hypnotic misuse, within the past 12 months
  • Significant medical or neurological conditions that may affect sleep or study outcomes (e.g., severe cardiovascular, respiratory, or neurological disease)
  • Any condition judged by the investigator to interfere with study participation, safety, or data validity
  • Night-shift workers or individuals with irregular sleep-wake schedules
  • Pregnancy or breastfeeding
  • Participation in another interventional clinical study within the past 30 days

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicenter, randomized, double-blind, sham-controlled clinical investigation designed to evaluate the effectiveness and safety of BELL-001, a digital therapeutic developed to improve symptoms of insomnia. Insomnia is a common sleep disorder that can significantly affect daytime functioning, mood, and overall quality of life. Many patients continue to have difficulties despite lifestyle changes or medication, and safer, non-pharmacological treatment options are increasingly needed.

Read full original descriptionShow less

BELL-001 is a smartphone-based therapeutic that delivers personalized auditory stimulation during the pre-sleep period. The device is intended to promote relaxation and support the transition into sleep by analyzing individual breathing patterns and providing synchronized sound feedback. The study will compare BELL-001 with a sham (placebo-like) digital device that looks identical but does not provide the active therapeutic functions.

Adults diagnosed with insomnia will be randomly assigned to either the BELL-001 group or the sham group. Participants will use the assigned device for four weeks. Throughout the study, sleep-related symptoms, daytime functioning, fatigue, and quality-of-life measures will be assessed. The primary outcome is the change in Insomnia Severity Index (ISI) scores after four weeks of treatment. Safety will be monitored regularly through participant reports and clinical evaluations.

This trial is being conducted at multiple hospitals in Korea and follows ethical guidelines, including review and approval by institutional review boards (IRBs). Participation is voluntary, and all individuals will provide informed consent before any study procedures begin. The results of this study are expected to provide key evidence for the clinical use of a digital, non-pharmacological intervention for adults with insomnia.

The 2 groups in the trial

  • BELL-001 Digital TherapeuticTreatment being tested

    Participants assigned to the experimental arm will use BELL-001, a smartphone-based digital therapeutic designed to provide personalized auditory stimulation synchronized with the user's breathing pattern. The intervention is administered nightly during the pre-sleep period for 4 weeks. The device delivers an active algorithm intended to reduce pre-sleep hyperarousal and support sleep initiation.

  • Sham Digital TherapeuticSham treatment, for comparison

    Participants assigned to the sham arm will use a visually identical digital device that does not deliver the active therapeutic algorithm. The sham device mimics the user interface and appearance of BELL-001 to maintain blinding but provides non-therapeutic audio output. Participants will use the device nightly during the pre-sleep period for 4 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Sham-Controlled, Pivotal Clinical Investigation to Evaluate the Efficacy and Safety of the Digital Therapeutic 'BELL-001' for Improving Symptoms in Patients With Insomnia
Publications
Record updated
27 August 2026